glp 1 drugs shortage FDA says that the GLP-1 is over The Multi-Sector Impacts of GLP-1RA
Description
Albiglutide: The HARMONY Outcomes trial (2018) reported a 22% MACE reduction (HR 0.78, 95% CI 0.680.90) in 9463 T2DM patients, driven by reduced MI [18]
(2022) suggests that GLP-1 RAs may be associated with a reduced risk of atrial arrhythmias
30 Jun 2026 QaseemA, ObleyAJ, Shamilyan T, Hicks LA, et.al.,Clinical Guidelines Committee ofthe American College of Physicians
The applications of GLP-1RAs extend far beyond diabetes management
We observe decreased liver inflammation when patients use these treatments 3 , and studies demonstrate a 12% reduction in dementia risk 1
Banking J.P
